Castle Biosciences reported Q1 2026 results after the bell on May 6 — a revenue beat against a guidance raise — yet the stock slid 3.6% on May 5 ahead of the print, extending what has been a flat-to-weak few weeks for a name down 34% year-to-date.
The headline numbers were constructive. Q1 revenue came in at $83.7M, clearing the $79.4M estimate. Adjusted EPS of -$0.49 was in line. Management raised full-year 2026 revenue guidance to $345M–$355M from $340M–$350M, bracketing the $345.7M consensus. A genuine beat-and-raise against a backdrop of significant year-to-date selling is the central tension heading into the post-earnings session.
Short positioning tells a mildly cautious story that has been building quietly. Short interest has risen about 4% over the past month to 5.2% of the free float — not extreme, but the drift has been steady and consistent, with shares short climbing from roughly 1.41M in early April to 1.52M now. Borrowing costs have been volatile but remain low at 0.74% annually, well off the intra-month spike that briefly touched 3.5% on April 29. Availability in the lending market is ample, with utilization near 2.4% — just below its 52-week high of 2.5%, meaning the pool of loanable shares is barely tapped. That rules out any squeeze dynamic. Options positioning is also relaxed: the put/call ratio at 0.26 is only modestly above its 20-day mean of 0.23 and sits near the middle of the year's range. Taken together, the positioning picture is cautious but not aggressive — no sign that large-scale directional bets have been placed ahead of this print.
The Street remains firmly on the buy side, though with some target compression. Every analyst on record carries a Buy or Outperform rating. The mean price target of $47.25 implies roughly 92% upside to the pre-earnings close of $24.60 — a wide gap that reflects how far the stock has fallen this year rather than unusual bullishness. The most recent action, from Canaccord Genuity in late April, trimmed the target from $50 to $40 while maintaining Buy — a signal the firm still sees strong recovery potential but was adjusting for near-term execution risk. Earlier this year, Baird, Guggenheim, and Lake Street had all raised targets into the $40–$52 range, a run-up that preceded the stock's slide. The EV/EBITDA multiple has compressed about 2.4x over the past 30 days, now at 16.8x. The company remains unprofitable on a P/E basis, though the bears' chief concern — lack of gastroenterology clinician awareness for the TissueCypher test — has been a recurring theme in the narrative.
CEO and founder Derek Maetzold sold just over $90,000 worth of shares in small tranches on April 21, following similar small sales on April 6. The transactions appear to be part of a pre-set programme rather than a directional signal: individual lots were tiny relative to the company's float, significance scores were low across all trades, and the 90-day net figure is actually positive at $2.87M in aggregate value. Institutional ownership is stable, with BlackRock at 10.2% and Vanguard at 7.3% as of March 31, both adding modestly. Wasatch Advisors trimmed by 82,000 shares in the same period, the largest reduction among top holders.
The last comparable earnings reaction — the February 2026 print — produced a 12% single-day drop followed by a further 15% decline over five days. The Q1 2026 numbers are materially better than that setup on both revenue and guidance, so what to watch now is whether the raised guide is enough to reverse a persistent de-rating trend, or whether the stock continues to trade at a wide discount to analyst targets until clinician adoption data becomes more visible.
See the live data behind this article on ORTEX.
Open CSTL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
